VERICIGUAT
Information current as at: 1 May 2025
PBAC meeting date: March 2022
Submission Details
- Brand name:
-
- Verquvo®
- Pharmaceutical company:
- Bayer Australia Ltd
- Condition/indication:
(therapeutic use) -
- Chronic heart failure
- PBAC Submission type:
- New listing (–)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2022
- Related medicines:
- --
Progress Details
-
Submission received for: - March 2022 PBAC meeting
-
Opportunity for consumer comment: - Open 24/11/2021 and close 27/01/2022 (see PBS Website)
-
PBAC meeting: - Held on 09/03/2022
-
PBAC outcome published: - Not Recommended (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a507
Page last updated: 31 October 2024